Supar
Supar has been studied in 1 paper since 2025: 1 observational study in people. The newest paper, Nov 3, 2025: “Soluble Urokinase Plasminogen Activator Receptor (suPAR), Lipoprotein(a), and Cardiovascular Outcomes in the Multi-Ethnic Study of Atherosclerosis (MESA)”.
1 paper studies it1 findingUpdated
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“elevated suPAR (>3 ng/mL) was associated with a 75% higher risk of the composite outcome (aHR 1.75; 95% CI 1.44–2.26)”
- 1 lab in 1 country
- Humans1
What is supar linked with?
1Studies link supar with 1 measure, most often composite cardiovascular outcome (all-cause death, CVD death, myocardial infarction, or stroke) (1 study).
Composite cardiovascular outcome (all-cause death, CVD death, myocardial infarction, or stroke)
upin humans1
1 study
Composite cardiovascular outcome (all-cause death, CVD death, myocardial infarction, or stroke)
upin humans1
Supar is linked with a higher risk of composite cardiovascular outcome (all-cause death, CVD death, myocardial infarction, or stroke) in humans (fully adjusted Cox models; mutually adjusted for Lp(a)) (aHR 1.75 (95% CI 1.44–2.26)).
“elevated suPAR (>3 ng/mL) was associated with a 75% higher risk of the composite outcome (aHR 1.75; 95% CI 1.44–2.26)”
Humansfully adjusted Cox models; mutually adjusted for Lp(a)>3 ng/mLn = 4,357
AHA Scientific Sessions 2025 abstract